Yukihiro Toi
Sendai, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 11, 2026
Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.
Journal: Journal of medical case reports
Published: November 28, 2025
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 05, 2025
Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.
Journal: Translational lung cancer research
Published: September 25, 2025
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L.
Journal: Clinical lung cancer
Published: September 12, 2025
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.
Journal: Cancer treatment and research communications
Published: August 21, 2025
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 06, 2025
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.
Journal: Translational lung cancer research
Published: May 31, 2025
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 02, 2025
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 31, 2025
Last Updated: 09/26/2026